TEVA-EZETIMIBE 10 MG
EZETIMIBE : 10 MG · DIN 02354101 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-EZETIMIBE?
TEVA-EZETIMIBE 10 MG contains EZETIMIBE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02354101, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 15-Sep-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-EZETIMIBE used for?
Adjunct to diet for primary hypercholesterolemia (alone or with statin/fenofibrate), Homozygous Familial Hypercholesterolemia (with statin), and Homozygous Sitosterolemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02354101 |
|---|---|
| Brand name | TEVA-EZETIMIBE |
| Generic / active ingredient | EZETIMIBE : 10 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AX09 EZETIMIBE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Sep-2014 |
How is it administered?
Recommended dose: 10 mg once daily orally, alone or with a statin/fenofibrate. Can be taken with or without food. Administer ≥2 hours before or ≥4 hours after bile acid sequestrants.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 header present but content truncated), typically room temperature.
How is it supplied?
Blisters of 30 tablets; HDPE bottles of 100 and 500 tablets.
Contraindications
Hypersensitivity to any ingredient; with statins: active liver disease or unexplained persistent transaminase elevations; statins/fenofibrate are contraindicated in pregnancy/nursing.
Warnings and precautions
Drug induced liver injury, pancreatitis, myopathy/rhabdomyolysis, severe cutaneous adverse reactions (SJS, TEN, DRESS), and anaphylaxis. Monitor liver function tests.
Is EZETIMIBE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C10AX09 EZETIMIBE. 18 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-EZETIMIBE | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02425610 |
| AG-EZETIMIBE | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02475898 |
| APO-EZETIMIBE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02427826 |
| AURO-EZETIMIBE | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02469286 |
| BIO-EZETIMIBE | 10 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02425211 |
| EZETIMIBE | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02422549 |
| EZETIMIBE | 10 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 02478544 |
| EZETIMIBE | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02431300 |
| EZETROL | 10 MG | Tablet | ORGANON CANADA INC. | MARKETED | DIN 02247521 |
| JAMP-EZETIMIBE | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02423235 |
Who else supplies EZETIMIBE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. EZETIMIBE appears in 673 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.